TrialThe oncologist2019

Phase II Study of Everolimus and Octreotide LAR in Patients with Nonfunctioning Gastrointestinal Neuroendocrine Tumors: The GETNE1003_EVERLAR Study.

Jaume Capdevila et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.